Neil Kumar - BridgeBio Pharma, Chief Executive Officer, Director
| 2CL Stock | EUR 35.24 0.36 1.03% |
CEO
Neil Kumar is Chief Executive Officer, Director of BridgeBio Pharma, since 2015.
| Age | 40 |
| Tenure | 10 years |
| Phone | 650 391 9740 |
| Web | http://www.bridgebio.com |
Neil Kumar Latest Insider Activity
Tracking and analyzing the buying and selling activities of Neil Kumar against BridgeBio Pharma, stock is an integral part of due diligence when investing in BridgeBio Pharma,. Neil Kumar insider activity provides valuable insight into whether BridgeBio Pharma, is net buyers or sellers over its current business cycle. Note, BridgeBio Pharma, insiders must abide by specific rules, including filing SEC forms every time they buy or sell BridgeBio Pharma,'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Neil Kumar few days ago Disposition of 326932 shares by Neil Kumar of BridgeBio Pharma at 36.287 subject to Rule 16b-3 | ||
Neil Kumar over a month ago Disposition of 4685725 shares by Neil Kumar of BridgeBio Pharma subject to Rule 16b-3 | ||
Neil Kumar over three months ago Disposition of 28148 shares by Neil Kumar of BridgeBio Pharma at 24.4 subject to Rule 16b-3 | ||
Neil Kumar over three months ago Disposition of 11197 shares by Neil Kumar of BridgeBio Pharma at 25.1288 subject to Rule 16b-3 |
BridgeBio Pharma, Management Efficiency
The company has return on total asset (ROA) of (31.81) % which means that it has lost $31.81 on every $100 spent on assets. This is way below average. BridgeBio Pharma,'s management efficiency ratios could be used to measure how well BridgeBio Pharma, manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | CEO Age | ||
| Alex Vetter | Cars Inc | 52 | |
Management Performance
| Return On Asset | -31.81 |
BridgeBio Pharma, Leadership Team
Elected by the shareholders, the BridgeBio Pharma,'s board of directors comprises two types of representatives: BridgeBio Pharma, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BridgeBio. The board's role is to monitor BridgeBio Pharma,'s management team and ensure that shareholders' interests are well served. BridgeBio Pharma,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BridgeBio Pharma,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Neil Kumar, Chief Executive Officer, Director | ||
| Richard Scheller, Chairman of Research and Development, Director | ||
| Michael Henderson, Chief Business Officer | ||
| Andrew Lo, Independent Director | ||
| Randal Scott, Independent Director | ||
| Uma Sinha, Chief Scientific Officer | ||
| Brenton Saunders, Independent Director | ||
| Jennifer Cook, Independent Director | ||
| Brian Stephenson, Chief Financial Officer, Principal Accounting Officer | ||
| Ali Satvat, Independent Director | ||
| Cameron Turtle, Senior Vice President - Portfolio Management and Corporate Development | ||
| James Momtazee, Independent Director | ||
| Eric Aguiar, Independent Director | ||
| Charles Homcy, Chairman of Pharmaceuticals, Lead Director | ||
| Ronald Daniels, Independent Director | ||
| Frank Mccormick, Chairman of Oncology |
BridgeBio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BridgeBio Pharma, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -31.81 | |||
| Operating Margin | (806.01) % | |||
| Current Valuation | 6.62 B | |||
| Shares Outstanding | 149.28 M | |||
| Shares Owned By Insiders | 7.47 % | |||
| Shares Owned By Institutions | 96.18 % | |||
| Price To Book | 108.28 X | |||
| Price To Sales | 100.89 X | |||
| Revenue | 62.73 M | |||
| Gross Profit | 8.25 M |
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Other Information on Investing in BridgeBio Stock
BridgeBio Pharma, financial ratios help investors to determine whether BridgeBio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BridgeBio with respect to the benefits of owning BridgeBio Pharma, security.